The FDA has approved tezepelumab (Tezspire – Amgen/AstraZeneca), a subcutaneously administered thymic stromal lymphopoietin (TSLP) blocker, for add-on maintenance treatment of inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) in patients ≥12 years old. It is the first TSLP blocker to be approved for this indication. Tezepelumab was approved for add-on maintenance treatment of severe asthma in 2021.

The FDA has approved Sinuva (Intersect ENT), a sinus implant that gradually releases the corticosteroid mometasone furoate over a 90-day period, for treatment of nasal polyps in adults who have had ethmoid sinus surgery. Propel, a sinus implant that releases mometasone furoate over 30 days, is FDA-approved to maintain the sinus opening after ethmoid sinus surgery; it is marketed by the same manufacturer as Sinuva.